Anticancer Agent 83, a potent inhibitor of LOX IMVI cell growth, demonstrates anticancer efficacy with a GI50 value of 0.15 mM. It disrupts mitochondrial membrane potential and induces DNA damage, thereby promoting apoptosis in leukemia cells [1].

Anticancer agent 83, also known as compound 4a, exhibits potent efficacy against a variety of human cancer cell lines when administered in concentrations ranging from 0.01 to 100 μM over 24 hours. It significantly inhibits cell viability in human colon carcinoma HCT116 p53 / cells (with P53 gene deletion, GI 50 = 8.4 μM), human epidermoid cervix carcinoma KB3-1 (GI 50 = 7.4 μM), human ovarian carcinoma Skov 3 (GI 50 = 10 μM), and human chronic myelogenous leukemia K562 cells (GI 50 = 5.4 μM). Additionally, a specific concentration of 0.5 μM of this agent for 24 hours disrupts DNA stability, induces apoptosis, and diminishes mitochondrial membrane potential in Jurkat cells. Through various assessments, including the Cell Viability Assay and Immunofluorescence, it was demonstrated that Anticancer agent 83 not only reduces cell viability with certain GI 50 values across the mentioned cell lines but also prompts morphological changes indicative of apoptosis, such as apoptotic bodies, membrane blebbing, and chromatin condensation, alongside DNA fragmentation in Jurkat T-cells.